Bausch & Lomb Corp

BLCO

Company Profile

  • Business description

    Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

  • Contact

    520 Applewood Crescent
    VaughanONL4K 4B4
    CAN

    T: +1 905 695-7700

    https://www.bausch.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Instruments & Supplies

    Fiscal Year End

    31 December 2026

    Employees

    13,500

Stocks News & Analysis

stocks

Undervalued Aussie e-commerce winner

Shares attractive due to near term profit margin increase and structural growth.
stocks

Our view on oil prices after Maduro is deposed

We’ve revisited our oil price assumptions after the news from Venezuela.
stocks

Nvidia: Full steam ahead with an impressive array of announcements at CES 2026

Our view of Nvidia at the current share price.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,018.0021.50-0.24%
CAC 408,237.4325.930.32%
DAX 4024,892.2023.510.09%
Dow JONES (US)49,462.08484.900.99%
FTSE 10010,122.73118.161.18%
HKSE26,383.82326.63-1.22%
NASDAQ23,547.17151.350.65%
Nikkei 22551,961.98556.10-1.06%
NZX 50 Index13,715.0251.440.38%
S&P 5006,944.8242.770.62%
S&P/ASX 2008,695.6027.90-0.32%
SSE Composite Index4,082.201.47-0.04%

Market Movers